Interviews

The shift toward fibrosis end points and noninvasive biomarkers in MASH trials may ease enrollment, improve assessment, and reduce biopsy use, Zobair M. Younossi, MD, said.

Setmelanotide cut BMI 16.5% in a trial for acquired hypothalamic obesity, easing hyperphagia, though adverse events require close monitoring.

Oyepeju Abioye-Akintola, MD, MSc explains how the Protocol & People initiative revealed unreadable consent forms as a fixable barrier to clinical and equitable trial enrollment.

Prior to receiving CAR T-cell therapy, patients undergo lymphodepletion chemotherapy, explained Kerry Rogers, MD, The James.

Katherine Wilemon, Family Heart Foundation, described the biggest unmet need when it comes to public awareness of Lp(a) and its associated risk factors.

Steven D. Nathan, MD, discusses inhaled treprostinil and why inhaled therapies could mark the next frontier in idiopathic pulmonary fibrosis (IPF) care.

The goal of transplant is to give rise to new immune cells capable of hunting down and destroying resistant leukemic cells, says Karilyn Larkin, MD.

Doris Hansen, MD, co-led "Bridging the Gaps in Health Equity and Access in Multiple Myeloma" on May 2, 2026, in Tampa, Florida.

Steven D. Nathan, MD, explains how recognizing early ILD symptoms, including Velcro crackles and dyspnea, can reduce delays in diagnosis.

UPMC and Birth Root Community Doula describe a 4-year partnership addressing food insecurity, housing, and maternal health disparities.

Steven D. Nathan, MD, discusses how multidisciplinary ILD care, particularly collaboration with rheumatologists, can improve early diagnosis and treatment.

Brittany G. Craiglow, MD, FAAD, discusses the psychiatric and psychosocial toll of alopecia in children and adolescents, and its impact on treatment initiation.

Rutgers SPH Dean Perry N. Halkitis, PhD, MS, MPH, shares his HIV survival story and why trusted messengers, not statistics, change health behavior.

Hans Lee, MD, lays out the tradeoffs in travel, time off therapy, and who each option realistically fits when looking at CAR T-cell and bispecific therapies.

Kerry Rogers, MD, unpacks why patients often misread CAR T-cell therapy in CLL as a guaranteed cure, and what the data really show.

A July AJMC study found metastatic cancer diagnoses significantly increase Medicaid spending, highlighting the potential budget benefits of earlier detection.

Early remdesivir treatment was associated with lower graft loss and cardiovascular events in kidney transplant recipients, noted Nitipong Permpalung, MD, MPH.

Denise Yardley, MD, on OPTIMA, Prosigna proliferation scoring, and telling patients an endocrine strategy fits how their tumor behaves.

Vicki Keedy, MD, speaks to sarcoma research funding gaps, delayed diagnosis, and why the European specialty center model outperforms US referral patterns.

Integrated specialty pharmacies have EHR access, faster prior authorizations, and built-in monitoring, Brooke Looney, PharmD, CSP, highlighted.

Clinical trial access remains the biggest barrier in sarcoma care, with travel and insurance limits keeping patients from open studies, says Vicki Keedy, MD.

David Zhang, MD, discusses the limitations of polygenic risk scores and remaining barriers to their clinical use in idiopathic pulmonary fibrosis.

Emily K. Curran, MD, addresses why patients with leukemia often need her more than their own primary care physician and what changes when they don’t.

Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, BCOP, and bispecifics will bring another shift.

Kanita Bourne, LCSW, discusses how implicit bias, missed depression signs, and expanded doula access are shaping Black maternal health outcomes.

David Zhang, MD, discusses how real-world EHR and biobank data could advance polygenic risk scores for IPF diagnosis and risk prediction.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, explains how GLP-1-based therapies are reshaping diabetes, obesity, and cardiometabolic care and what that means for coverage decisions.

Swarup Kumar, MD, also details treating incarcerated patients with bispecifics and pursuing cure-focused therapy sequencing in myeloma.